Approaches for the design of novel anti-atherogenic compounds.
Biessen
E A
EA
Division of Biopharmaceutics, Leiden-Amsterdam Center for Drug Research, Sylvius Laboratory, University of Leiden, The Netherlands.
Sliedregt
L A
LA
Van Berkel
T J
TJ
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000924:Anticholesteremic Agents / Q000737:chemistry / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology; D001161:Arteriosclerosis / Q000188:drug therapy*; D002784:Cholesterol / Q000096:biosynthesis / Q000378:metabolism*; D015195:Drug Design; D013186:Farnesyl-Diphosphate Farnesyltransferase / Q000037:antagonists & inhibitors; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D047029:Lactams, Macrocyclic; D008074:Lipoproteins / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D015394:Molecular Structure
D000900:Anti-Bacterial Agents; D000924:Anticholesteremic Agents; D000975:Antioxidants; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D047029:Lactams, Macrocyclic; D008074:Lipoproteins; D002784:Cholesterol; D013186:Farnesyl-Diphosphate Farnesyltransferase